Home › Triple-Negative Breast Cancer › New Jersey
Triple-Negative Breast Cancer clinical trials in New Jersey
20 studies for Triple-Negative Breast Cancer are looking for participants at sites in New Jersey.
Cities in New Jersey
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START New Jersey, East Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- John Theurer Cancer Center at Hackensack UMC, Hackensack
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Cooper Hospital Univ Med Ctr, MD Anderson at Cooper Voorhees, Voorhees Township
Recruiting
Ages 30 and older · Women · Updated Sep 25, 2026 · NCT02945579A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Hackensack Univ Medical Center (HUMC) ( Site 0007), Hackensack
- Rutgers Cancer Institute of New Jersey ( Site 0076), New Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0082), Hackensack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06841354A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
- Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06246968Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Regional Cancer Care Associates LLC, East Brunswick
- Hunterdon Medical Center, Flemington
- Rutgers Health, New Brunswick
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
- Hackensack Meridian Health, Hackensack
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05570253Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Summit Medical Group, Florham Park
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07211178A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- John Theurer Cancer Center, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04895709A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 2
Ages 70 and older · All sexes · Updated Aug 17, 2026 · NCT07768436Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- MD Anderson Cancer Center at Cooper- Two Cooper Plaza, Camden
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of LY4175408 in Participants With Advanced Cancer
- John Theurer Cancer Center At Hackensack UMC, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- United Theranostics, Princeton
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT07311993I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT01042379Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 27, 2026 · NCT03808337A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
RecruitingPhase 2
Ages 18 and older · Women · Updated Feb 17, 2026 · NCT04683679A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 19, 2025 · NCT06568692From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.